Report of the AAPS Guidance Forum on the FDA draft guidance for industry:“drug products, including biological products, that contain nanomaterials”
Open accessThe DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
To guide developers of innovative and generic drug products that contain nanomaterials, the U.S. Food and Drug Administration issued the draft guidance for industry titled: "Drug Products, Including Biological Products, that Contain Nanomaterials" in December 2017. During the AAPS Guidance Forum on September 11, 2018, participants from industry, academia, and regulatory bodies discussed this draft guidance in an open setting. Two questions raised by the AAPS membership were discussed in more detail: what is the appropriate regulatory pathway for approval of drug products containing nanomaterials, and how to determine critical quality attributes (CQAs) for nanomaterials? During the meeting, clarification was provided on how the new FDA center-led guidance relates to older, specific nanomaterial class, or specific product-related guidances. The lively discussions concluded with some clear observations and recommendations: (I) Important lessons can be learned from how CQAs were determined for, e.g., biologics. (II) Publication of ongoing scientific discussions on strategies and studies determining CQAs of drug products containing nanomaterials will significantly strengthen the science base on this topic. Furthermore, (III) alignment on a global level on how to address new questions regarding nanomedicine development protocols will add to efficient development and approval of these much needed candidate nanomedicines (innovative and generic). Public meetings such as the AAPS Guidance Forum may serve as the place to have these discussions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Regulatory appraisal has to deal with its impact on safety and efficacy profiles. This calls for increased scrutiny and rigor in the review process [288, 291, 292].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [292]
The cited source says what the claim attributes to it.
In the citing paper
“Encapsulation in nanoparticles changes the size, surface properties, and other characteristics which affect in vivo drug behavior when compared to traditional formulations composed of low molecular weight API and excipients.”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [292]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The evolving landscape of drug products containing nanomaterials in the United States
D'Mello, S. R., Cruz, C. N., Chen, M.-L., Kapoor, M., Lee, S. L., & Tyner, K. M. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.67 · Cited by 345
Self-citationLiposomal drug product development and quality: current US experience and perspective
Kapoor, M., Lee, S. L., & Tyner, K. M. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0049-9 · Cited by 116
Self-citationIn Vitro and In Vivo Characterizations of Pegylated Liposomal Doxorubicin
Jiang, W., Lionberger, R., & Yu, L. X. (2011) · Bioanalysis · doi:10.4155/bio.10.204 · Cited by 101
Self-citationEquivalence of complex drug products: advances in and challenges for current regulatory frameworks
Hussaarts, L., Mühlebach, S., Shah, V. P., McNeil, S., Borchard, G., Flühmann, B., Weinstein, V., Neervannan, S., Griffiths, E., Jiang, W., et al. (2017) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13347 · Cited by 88
Self-citationA Quality by Design Approach to Developing and Manufacturing Polymeric Nanoparticle Drug Products
Troiano, G., Nolan, J., Parsons, D. M., Hoven, C. V. G., & Zale, S. E. (2016) · The AAPS Journal · doi:10.1208/s12248-016-9969-z · Cited by 84
Lee, J., Kang, H. A., Bae, J. S., Kim, K. D., Lee, K. H., Lim, K. J., Choo, M. J., & Chang, S.-J. (2018) · mAbs · doi:10.1080/19420862.2018.1440170 · Cited by 59
Vandekerckhove, K., Seidl, A., Gutka, H. J., Kumar, M., Gratzl, G., Keire, D. A., Coffey, T. S., & Kuehne, H. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0230-9 · Cited by 54
Physicochemical Characterization of Iron Carbohydrate Colloid Drug Products
Zou, P., Tyner, K. M., Raw, A., & Lee, S. (2017) · The AAPS Journal · doi:10.1208/s12248-017-0126-0 · Cited by 39
Self-citationProcess signatures in glatiramer acetate synthesis: structural and functional relationships
Campos‐García, V. R., Herrera-Fernández, D., la Garza, C. E. E., González, G., Vallejo‐Castillo, L., Avila, S., Muñoz‐García, L., Medina‐Rivero, E., Pérez, N. O., Gracia‐Mora, I., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-12416-1 · Cited by 32
Marden, E., Ntai, I., Scott, B., & Flühmann, B. (2018) · The AAPS Journal · doi:10.1208/s12248-018-0255-0 · Cited by 32
Cited by
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
“This calls for increased scrutiny and rigor in the review process [288,291,292].”
BackgroundDelivering the power of nanomedicine to patients today
Germain, M., Caputo, F., Metcalfe, S., Tosi, G., Spring, K., Åslund, A. K. O., Pottier, A., Schiffelers, R., Ceccaldi, A., & Schmid, R. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.007 · Cited by 405
A translational framework to DELIVER nanomedicines to the clinic
Joyce, P., Allen, C. J., Alonso, M. J., Ashford, M., Bradbury, M. S., Germain, M., Kavallaris, M., Langer, R., Lammers, T., Peracchia, M. T., et al. (2024) · Nature Nanotechnology · doi:10.1038/s41565-024-01754-7 · Cited by 333
Joshi, A. S., Singh, P., & Mijakovic, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207658 · Cited by 327
Nanocarriers for ocular drug delivery: current status and translational opportunity
Gorantla, S., Rapalli, V. K., Waghule, T., Singh, P. P., Dubey, S. K., Saha, R. N., & Singhvi, G. (2020) · RSC Advances · doi:10.1039/d0ra04971a · Cited by 313
Metadata
- Authors
- de Vlieger, J. S. B., Crommelin, D. J. A., Tyner, K., Drummond, D. C., Jiang, W., McNeil, S. E., Neervannan, S., Crist, R. M., & Shah, V. P.
- Affiliations
- Utrecht University (NL)
- United States Food and Drug Administration (US)
- Merrimack Pharmaceuticals (United States) (US)
- Frederick National Laboratory for Cancer Research (US)
- ORCID
- Venue
- The AAPS Journal
- Published
- 2019-04-17
- Volume
- 21
- Issue
- 4
- Pages
- 56-56
- ISSN
- 1550-7416 (ISSN-L)
- PMC
- PMC6470106
- OpenAlex
- W2936171216
- Cited by
- 100
- References
- 16
- Citations by year
- 2026: 37 · 2025: 20 · 2024: 6 · 2023: 9 · 2022: 9 · 2021: 9 · 2020: 7 · 2019: 3
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- The AAPS Journal (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services (HHSN261200800001E)
- National Cancer Institute (No. HHSN261200800001E, Contract No.,HHSN261200800001E, HHSN261200800001E))
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
- Physical Sciences › Materials Science › General Materials Science › Nanotechnology research and applications
- Keywords
- nanomedicine regulation, critical quality attributes, regulatory approval pathways, generic drugs, biologics, regulatory science
- MeSH terms
- Biological Products, Drug Industry, United States, United States Food and Drug Administration, Drugs, Generic, Drug Approval, Guidelines as Topic, Government Regulation, Nanostructures
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Report of the AAPS Guidance Forum on the FDA draft guidance for industry:“drug products, including biological products, that contain nanomaterials”. https://app.cochat.ai/papers/10.1208/s12248-019-0329-7
- The paper
- de Vlieger, J. S. B., Crommelin, D. J. A., Tyner, K., Drummond, D. C., Jiang, W., McNeil, S. E., Neervannan, S., Crist, R. M., & Shah, V. P. (2019). Report of the AAPS Guidance Forum on the FDA draft guidance for industry:“drug products, including biological products, that contain nanomaterials”. The AAPS Journal. https://doi.org/10.1208/s12248-019-0329-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.